A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: a subanalysis of Asian patients versus the global population in checkmate 141 - Kiyota, N; Hasegawa, Y; Takahashi, S (Oral Oncol, 2017)
, et al.